Rising uncertainty pushed by US tariffs and proposed “most-favoured nation” pricing is prompting pharmaceutical firms to delay funding and product launches in Europe.
US tariffs and pricing strain are inflicting uncertainty for the pharma sector, which can gradual funding choices and delay affected person entry to new medicines in Europe, in keeping with a brand new trade survey carried out for the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE).
The evaluation, carried out by Copenhagen Economics roughly estimates that its members added €98 billion to the EU’s GDP in 2024 and supported round 678,000 jobs when direct (€59B, 225k jobs), oblique (€24B, 276k jobs) and induced results (€16B, 177k jobs) have been taken under consideration.
The research underscores how the sector stays one among Europe’s most efficient, with excessive productiveness pushed by substantial funding in analysis and specialised expertise. Nonetheless, 57% of respondents count on R&D expenditure to say no, and none anticipated a rise in these unsure instances.
The 2 fundamental drags on funding are the US imposition of 15% tariffs on non-generic medicines and what the Trump administration refers to as “most-favoured nation” (MFN) pricing. The survey responses counsel these insurance policies could immediate firms to rethink funding and launch methods, doubtlessly shifting actions away from…
Share this text:
